$4.78
+0.07
(+1.49%)▲
0.84%
Downside
Day's Volatility :1.66%
Upside
0.83%
17.57%
Downside
52 Weeks Volatility :70.42%
Upside
64.11%
Period | Evotec Se - Adr | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.18% | 6.5% | 0.0% |
6 Months | -40.38% | 7.1% | 0.0% |
1 Year | -64.16% | 9.8% | 0.0% |
3 Years | -78.59% | 14.2% | -20.2% |
Market Capitalization | 1.7B |
Book Value | $6.25 |
Earnings Per Share (EPS) | -0.28 |
Wall Street Target Price | 11.64 |
Profit Margin | -11.68% |
Operating Margin TTM | -8.72% |
Return On Assets TTM | 0.03% |
Return On Equity TTM | -7.91% |
Revenue TTM | 776.6M |
Revenue Per Share TTM | 2.19 |
Quarterly Revenue Growth YOY | -2.3% |
Gross Profit TTM | 151.5M |
EBITDA | 43.4M |
Diluted Eps TTM | -0.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.16 |
EPS Estimate Next Year | 0.06 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.09 |
What analysts predicted
Upside of 143.51%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 429.5M | ↑ 45.71% |
Net Income | 96.3M | ↑ 247.0% |
Net Profit Margin | 22.42% | ↑ 13.0% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 500.1M | ↑ 18.92% |
Net Income | 42.7M | ↓ 54.67% |
Net Profit Margin | 8.55% | ↓ 13.87% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 616.1M | ↑ 12.2% |
Net Income | 7.7M | ↓ 83.55% |
Net Profit Margin | 1.25% | ↓ 7.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 699.9M | ↑ 23.38% |
Net Income | 244.1M | ↑ 3332.78% |
Net Profit Margin | 34.87% | ↑ 33.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 805.0M | ↑ 21.59% |
Net Income | -188.2M | ↓ 181.51% |
Net Profit Margin | -23.38% | ↓ 58.25% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 781.4M | ↑ 3.99% |
Net Income | -83.9M | ↓ 52.23% |
Net Profit Margin | -10.74% | ↑ 12.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 257.8M | ↑ 38.42% |
Net Income | -29.1M | ↓ 42.46% |
Net Profit Margin | -11.3% | ↑ 15.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 262.5M | ↑ 0.0% |
Net Income | -29.7M | ↑ 0.0% |
Net Profit Margin | -11.3% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 185.8M | ↓ 29.25% |
Net Income | -16.3M | ↓ 45.12% |
Net Profit Margin | -8.77% | ↑ 2.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 196.3M | ↑ 15.27% |
Net Income | -39.0M | ↑ 160.94% |
Net Profit Margin | -19.85% | ↓ 11.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 201.3M | ↑ 2.57% |
Net Income | -16.1M | ↓ 58.59% |
Net Profit Margin | -8.01% | ↑ 11.84% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 225.4M | ↑ 3.68% |
Net Income | -22.3M | ↑ 28.16% |
Net Profit Margin | -9.9% | ↓ 1.89% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 883.1M | ↑ 15.68% |
Total Liabilities | 397.0M | ↑ 3.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 52.99% |
Total Liabilities | 788.5M | ↑ 102.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 23.88% |
Total Liabilities | 910.3M | ↑ 5.14% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 52.79% |
Total Liabilities | 971.1M | ↑ 15.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 0.99% |
Total Liabilities | 1.1B | ↑ 24.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 1.85% |
Total Liabilities | 1.2B | ↑ 10.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↓ 0.24% |
Total Liabilities | 1.1B | ↑ 3.47% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 0.0% |
Total Liabilities | 1.2B | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 1.95% |
Total Liabilities | 1.2B | ↑ 5.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↓ 2.03% |
Total Liabilities | 1.1B | ↓ 1.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 1.98% |
Total Liabilities | 1.2B | ↑ 5.88% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↓ 3.93% |
Total Liabilities | 1.2B | ↓ 6.53% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 178.7M | ↑ 1342.93% |
Investing Cash Flow | -44.8M | ↓ 85.46% |
Financing Cash Flow | -89.0M | ↓ 132.3% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 47.3M | ↓ 72.98% |
Investing Cash Flow | -97.0M | ↑ 121.4% |
Financing Cash Flow | 236.7M | ↓ 371.67% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 55.0M | ↑ 5.93% |
Investing Cash Flow | -190.8M | ↑ 79.02% |
Financing Cash Flow | 303.1M | ↑ 16.64% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 138.4M | ↑ 173.33% |
Investing Cash Flow | -276.2M | ↑ 57.24% |
Financing Cash Flow | 451.2M | ↑ 61.69% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.9M | ↑ 743.66% |
Investing Cash Flow | 15.4M | ↓ 106.31% |
Financing Cash Flow | -2.1M | ↓ 57.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.6M | ↑ 0.0% |
Investing Cash Flow | 15.7M | ↑ 0.0% |
Financing Cash Flow | -2.1M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↓ 81.5% |
Investing Cash Flow | 15.7M | ↑ 0.0% |
Financing Cash Flow | 15.2M | ↓ 812.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 20.8M | ↓ 434.77% |
Investing Cash Flow | -15.8M | ↓ 209.48% |
Financing Cash Flow | 43.4M | ↑ 210.75% |
Sell
Neutral
Buy
Evotec Se - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Evotec Se - Adr | 0.21% | -40.38% | -64.16% | -78.59% | -78.59% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Evotec Se - Adr | 485.75 | NA | NA | -0.16 | -0.08 | 0.0 | NA | 6.25 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Evotec Se - Adr | Buy | $1.7B | -78.59% | 485.75 | -11.68% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Evotec Se - Adr
Revenue is up for the last 4 quarters, 170.27M → 208.72M (in $), with an average increase of 6.4% per quarter
Netprofit is down for the last 2 quarters, -16.13M → -20.67M (in $), with an average decrease of 28.2% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 109.7%
Mubadala Investment Company PJSC
Morgan Stanley - Brokerage Accounts
Millennium Management LLC
Optiver Holding B.V.
DCF Advisers, LLC
BlackRock Inc
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.
Organization | Evotec Se - Adr |
Employees | 5055 |
CEO | Dr. Mario Polywka DPHIL, Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$4.78
+1.49%
Keyarch Acquisition Corp
$4.78
+1.49%
Connexa Sports Technologies Inc
$4.78
+1.49%
Us Value Etf
$4.78
+1.49%
First Wave Biopharma Inc
$4.78
+1.49%
Global X Msci Next Emerging
$4.78
+1.49%
Fat Projects Acquisition Corp
$4.78
+1.49%
Capital Link Global Fintech
$4.78
+1.49%
Applied Uv Inc
$4.78
+1.49%